Literature DB >> 11137998

A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes.

H X Liu1, L Cartegni, M Q Zhang, A R Krainer.   

Abstract

Point mutations can generate defective and sometimes harmful proteins. The nonsense-mediated mRNA decay (NMD) pathway minimizes the potential damage caused by nonsense mutations. In-frame nonsense codons located at a minimum distance upstream of the last exon-exon junction are recognized as premature termination codons (PTCs), targeting the mRNA for degradation. Some nonsense mutations cause skipping of one or more exons, presumably during pre-mRNA splicing in the nucleus; this phenomenon is termed nonsense-mediated altered splicing (NAS), and its underlying mechanism is unclear. By analyzing NAS in BRCA1, we show here that inappropriate exon skipping can be reproduced in vitro, and results from disruption of a splicing enhancer in the coding sequence. Enhancers can be disrupted by single nonsense, missense and translationally silent point mutations, without recognition of an open reading frame as such. These results argue against a nuclear reading-frame scanning mechanism for NAS. Coding-region single-nucleotide polymorphisms (cSNPs) within exonic splicing enhancers or silencers may affect the patterns or efficiency of mRNA splicing, which may in turn cause phenotypic variability and variable penetrance of mutations elsewhere in a gene.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11137998     DOI: 10.1038/83762

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  135 in total

1.  Stop codons affect 5' splice site selection by surveillance of splicing.

Authors:  Binghui Li; Chaim Wachtel; Elana Miriami; Galit Yahalom; Gilgi Friedlander; Gil Sharon; Ruth Sperling; Joseph Sperling
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

Review 2.  RNA-protein interactions that regulate pre-mRNA splicing.

Authors:  Ravinder Singh
Journal:  Gene Expr       Date:  2002

Review 3.  Genetic polymorphisms of adrenergic receptors.

Authors:  E M Garland; I Biaggioni
Journal:  Clin Auton Res       Date:  2001-04       Impact factor: 4.435

4.  Identification of polymorphisms within the bovine prion protein gene (Prnp) by DNA sequencing and genotyping by MALDI-TOF-MS.

Authors:  Andreas Humeny; Katrin Schiebel; Silke Seeber; Cord-Michael Becker
Journal:  Neurogenetics       Date:  2002-03       Impact factor: 2.660

5.  Conserved sequence elements associated with exon skipping.

Authors:  Elana Miriami; Hanah Margalit; Ruth Sperling
Journal:  Nucleic Acids Res       Date:  2003-04-01       Impact factor: 16.971

Review 6.  Nuclear translation: what is the evidence?

Authors:  James E Dahlberg; Elsebet Lund; Elizabeth B Goodwin
Journal:  RNA       Date:  2003-01       Impact factor: 4.942

Review 7.  Emerging roles of BRCA1 alternative splicing.

Authors:  T I Orban; E Olah
Journal:  Mol Pathol       Date:  2003-08

8.  BRCA2 T2722R is a deleterious allele that causes exon skipping.

Authors:  James D Fackenthal; Luca Cartegni; Adrian R Krainer; Olufunmilayo I Olopade
Journal:  Am J Hum Genet       Date:  2002-07-19       Impact factor: 11.025

Review 9.  Regulation of alternative RNA splicing by exon definition and exon sequences in viral and mammalian gene expression.

Authors:  Zhi-Ming Zheng
Journal:  J Biomed Sci       Date:  2004 May-Jun       Impact factor: 8.410

10.  Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.

Authors:  Kelly L Bolton; Georgia Chenevix-Trench; Cindy Goh; Siegal Sadetzki; Susan J Ramus; Beth Y Karlan; Diether Lambrechts; Evelyn Despierre; Daniel Barrowdale; Lesley McGuffog; Sue Healey; Douglas F Easton; Olga Sinilnikova; Javier Benítez; María J García; Susan Neuhausen; Mitchell H Gail; Patricia Hartge; Susan Peock; Debra Frost; D Gareth Evans; Rosalind Eeles; Andrew K Godwin; Mary B Daly; Ava Kwong; Edmond S K Ma; Conxi Lázaro; Ignacio Blanco; Marco Montagna; Emma D'Andrea; Maria Ornella Nicoletto; Sharon E Johnatty; Susanne Krüger Kjær; Allan Jensen; Estrid Høgdall; Ellen L Goode; Brooke L Fridley; Jennifer T Loud; Mark H Greene; Phuong L Mai; Angela Chetrit; Flora Lubin; Galit Hirsh-Yechezkel; Gord Glendon; Irene L Andrulis; Amanda E Toland; Leigha Senter; Martin E Gore; Charlie Gourley; Caroline O Michie; Honglin Song; Jonathan Tyrer; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Ulf Kristoffersson; Håkan Olsson; Åke Borg; Douglas A Levine; Linda Steele; Mary S Beattie; Salina Chan; Robert L Nussbaum; Kirsten B Moysich; Jenny Gross; Ilana Cass; Christine Walsh; Andrew J Li; Ronald Leuchter; Ora Gordon; Montserrat Garcia-Closas; Simon A Gayther; Stephen J Chanock; Antonis C Antoniou; Paul D P Pharoah
Journal:  JAMA       Date:  2012-01-25       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.